DK3419978T3 - Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere - Google Patents

Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere Download PDF

Info

Publication number: DK3419978T3
Authority: DK; Denmark
Prior art keywords: pyrazin; pyrazolo; derivatives; jak inhibitors; jak
Prior art date: 2016-02-24

Application number

DK17705705.6T

Other languages

English (en)

Inventor

Matthew Frank Brown

Alpay DERMENCI

Andrew Fensome

Brian Stephen Gerstenberger

Matthew Merrill Hayward

Dafydd Rhys Owen

Stephen Wayne Wright

Li Huang Xing

Xiaojing Yang

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-24

Filing date

2017-02-10

Publication date

2020-06-02

2017-02-10 Application filed by Pfizer filed Critical Pfizer

2020-06-02 Application granted granted Critical

2020-06-02 Publication of DK3419978T3 publication Critical patent/DK3419978T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

DK17705705.6T 2016-02-24 2017-02-10 Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere DK3419978T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662299130P	2016-02-24	2016-02-24
PCT/IB2017/050748 WO2017144995A1 (en)	2016-02-24	2017-02-10	Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors

Publications (1)

Publication Number	Publication Date
DK3419978T3 true DK3419978T3 (da)	2020-06-02

Family

ID=58054385

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17705705.6T DK3419978T3 (da)	2016-02-24	2017-02-10	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere

Country Status (44)

Country	Link
US (4)	US10144738B2 (da)
EP (2)	EP3712153B1 (da)
JP (1)	JP6505956B2 (da)
KR (1)	KR102128671B1 (da)
CN (1)	CN109071546B (da)
AR (1)	AR107714A1 (da)
AU (1)	AU2017222417B2 (da)
CA (1)	CA2958490C (da)
CL (1)	CL2018002358A1 (da)
CO (1)	CO2018008799A2 (da)
CR (1)	CR20180372A (da)
CU (1)	CU24511B1 (da)
CY (1)	CY1122949T1 (da)
DK (1)	DK3419978T3 (da)
DO (1)	DOP2018000187A (da)
EA (1)	EA035036B1 (da)
EC (1)	ECSP18072109A (da)
ES (1)	ES2794779T3 (da)
GE (1)	GEP20217242B (da)
HR (1)	HRP20200781T1 (da)
HU (1)	HUE049305T2 (da)
IL (1)	IL260923B (da)
LT (1)	LT3419978T (da)
MA (2)	MA43668B1 (da)
MD (1)	MD3419978T2 (da)
ME (1)	ME03743B (da)
MX (1)	MX383747B (da)
MY (1)	MY189118A (da)
NI (1)	NI201800080A (da)
NZ (1)	NZ744349A (da)
PH (1)	PH12018501788A1 (da)
PL (1)	PL3419978T3 (da)
PT (1)	PT3419978T (da)
RS (1)	RS60261B1 (da)
RU (1)	RU2718902C2 (da)
SG (1)	SG11201806307YA (da)
SI (1)	SI3419978T1 (da)
SV (1)	SV2018005726A (da)
TN (1)	TN2018000295A1 (da)
TW (1)	TWI665201B (da)
UA (1)	UA119835C2 (da)
UY (1)	UY37133A (da)
WO (1)	WO2017144995A1 (da)
ZA (1)	ZA201804972B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3419978T3 (da)	2016-02-24	2020-06-02	Pfizer	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
EP4467565A3 (en)	2016-12-21	2025-03-12	Amgen Inc.	Anti-tnf alpha antibody formulations
KR20200139153A (ko)	2018-02-27	2020-12-11	인사이트 코포레이션	A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
AR117398A1 (es) *	2018-03-12	2021-08-04	Abbvie Inc	Inhibidores de la señalización mediada por tirosina cinasa 2
WO2019219517A1 (en)	2018-05-17	2019-11-21	Bayer Aktiengesellschaft	Substituted dihydropyrazolo pyrazine carboxamide derivatives
JP7391046B2 (ja)	2018-05-18	2023-12-04	インサイト・コーポレイション	Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
CN117304191A (zh)	2018-07-05	2023-12-29	因赛特公司	作为a2a/a2b抑制剂的稠合吡嗪衍生物
TW202033198A (zh)	2018-10-17	2020-09-16	美商美國禮來大藥廠	以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AU2020256720B2 (en) *	2019-04-12	2022-09-01	PrimeGene (Beijing) Co. Ltd.	Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
WO2020222773A1 (en)	2019-04-30	2020-11-05	Celgene Corporation	Combination therapies comprising apremilast and tyk2 inhibitors
US20250032492A1 (en) *	2019-09-11	2025-01-30	Pfizer Inc.	Treatment of hidradenitis with jak inhibitors
TW202135816A (zh) *	2019-12-18	2021-10-01	美商輝瑞股份有限公司	以激酶抑制劑治療潰瘍性結腸炎
US20230149407A1 (en)	2020-04-04	2023-05-18	Pfizer Inc.	Methods of Treating Coronavirus Disease 2019
ES3038166T3 (en)	2020-04-08	2025-10-09	Pfizer	Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
JP2023542298A (ja) *	2020-09-11	2023-10-06	プルモシムセラピューティクスリミテッドライアビリティカンパニー	肺高血圧症を治療又は予防する組成物及び方法
CN112592345B (zh) *	2020-12-07	2024-09-13	嘉兴特科罗生物科技有限公司	一种三氮唑并吡嗪类化合物及其用途
TW202241859A (zh) *	2021-01-29	2022-11-01	美商富曼西公司	用於製備５－溴－２－（３－氯－吡啶－２－基）－２ｈ－吡唑－３－甲酸之方法
EP4284802A4 (en) *	2021-02-01	2025-01-01	Janssen Biotech, Inc.	SMALL MOLECULE INHIBITORS OF SALT-INDUCIBLE KINASES
TWI859521B (zh)	2021-03-30	2024-10-21	美商輝瑞股份有限公司	治療白斑病之方法
MX2024004993A (es)	2021-10-25	2024-05-07	Kymera Therapeutics Inc	Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
CN118317960A (zh) *	2021-11-12	2024-07-09	海南康哲美丽科技有限公司	吡唑并环化合物及其应用
KR20260009361A (ko) *	2023-05-12	2026-01-19	씨엠에스 리서치 앤드 디벨롭먼트 피티이. 리미티드	피라졸로피라진 화합물 및 이의 결정형의 제조 방법
WO2025034912A2 (en)	2023-08-07	2025-02-13	Cogent Biosciences, Inc.	Compounds for fgfr inhibition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5442448B2 (ja)	2006-12-22	2014-03-12	アステックス、セラピューティックス、リミテッド	Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
AR066879A1 (es) *	2007-06-08	2009-09-16	Novartis Ag	Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
TW201612182A (en)	2008-06-10	2016-04-01	Abbvie Inc	Novel tricyclic compounds
ES2378513T3 (es)	2008-08-06	2012-04-13	Pfizer Inc.	Compuestos 2-heterociclilamino piracinas sustituidas en posiciÃ³n 6 como inhibidores de CHK-1
WO2010117787A2 (en)	2009-03-30	2010-10-14	The Brigham And Women's Hospital, Inc.	Inhibiting eph b-3 kinase
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2558468B1 (en) *	2010-04-14	2015-04-01	Array Biopharma, Inc.	5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
JP2014528475A (ja) *	2011-10-12	2014-10-27	アレイバイオファーマ、インコーポレイテッド	５，７置換イミダゾ［１，２−ｃ］ピリミジン
JP6096879B2 (ja)	2012-03-28	2017-03-15	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	二環式ピラジノン誘導体
JPWO2013146963A1 (ja) *	2012-03-28	2015-12-14	武田薬品工業株式会社	複素環化合物
ES2656192T3 (es)	2013-07-31	2018-02-26	Gilead Sciences, Inc.	Inhibidores de SKY
TW201605811A (zh)	2013-12-11	2016-02-16	阿爾米雷爾有限公司	作為jak抑制劑之吡唑并嘧啶-2基衍生物
US9856263B2 (en) *	2014-04-28	2018-01-02	Pfizer Inc.	Heteroaromatic compounds and their use as dopamine D1 ligands
WO2016009028A1 (fr)	2014-07-17	2016-01-21	Valeo Systèmes d'Essuyage	Balai plat caréné d'essuie-glace
DK3227297T3 (da) *	2014-12-05	2021-04-06	Array Biopharma Inc	4,6-substitueret-pyrazolo[1,5-a]pyraziner som janus kinase-inhibitorer
WO2016119707A1 (en)	2015-01-29	2016-08-04	Hutchison Medipharma Limited	Novel heteroaryl and heterocycle compounds, compositions and methods
EP3256475A4 (en)	2015-02-13	2019-02-13	Dana-Farber Cancer Institute, Inc.	LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB201504565D0 (en)	2015-03-18	2015-05-06	Takeda Pharmaceutical	Novel compounds
HUE044240T2 (hu)	2015-04-29	2019-10-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus kináz (JAK) inhibitorok
WO2017108723A2 (en)	2015-12-22	2017-06-29	F. Hoffmann-La Roche Ag	PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
DK3419978T3 (da)	2016-02-24	2020-06-02	Pfizer	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
JP7193460B2 (ja)	2016-12-23	2022-12-20	プレキシコンインコーポレーテッド	Ｃｄｋ８調節およびその適応症のための化合物および方法
CN110267960B (zh)	2017-01-18	2022-04-26	阿雷生物药品公司	作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018234342A1 (en)	2017-06-21	2018-12-27	F. Hoffmann-La Roche Ag	ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4
US11254668B2 (en)	2017-08-14	2022-02-22	Pfizer Inc.	Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives

2017
- 2017-02-10 DK DK17705705.6T patent/DK3419978T3/da active
- 2017-02-10 CU CU2018000078A patent/CU24511B1/es unknown
- 2017-02-10 PL PL17705705T patent/PL3419978T3/pl unknown
- 2017-02-10 AU AU2017222417A patent/AU2017222417B2/en active Active
- 2017-02-10 MA MA43668A patent/MA43668B1/fr unknown
- 2017-02-10 HR HRP20200781TT patent/HRP20200781T1/hr unknown
- 2017-02-10 SG SG11201806307YA patent/SG11201806307YA/en unknown
- 2017-02-10 CN CN201780013165.4A patent/CN109071546B/zh active Active
- 2017-02-10 MY MYPI2018702937A patent/MY189118A/en unknown
- 2017-02-10 CO CONC2018/0008799A patent/CO2018008799A2/es unknown
- 2017-02-10 SI SI201730289T patent/SI3419978T1/sl unknown
- 2017-02-10 EP EP20168877.7A patent/EP3712153B1/en active Active
- 2017-02-10 EA EA201891463A patent/EA035036B1/ru unknown
- 2017-02-10 RU RU2018130547A patent/RU2718902C2/ru active
- 2017-02-10 KR KR1020187024431A patent/KR102128671B1/ko active Active
- 2017-02-10 JP JP2018544300A patent/JP6505956B2/ja active Active
- 2017-02-10 MX MX2018010236A patent/MX383747B/es unknown
- 2017-02-10 UA UAA201808148A patent/UA119835C2/uk unknown
- 2017-02-10 ME MEP-2020-97A patent/ME03743B/me unknown
- 2017-02-10 ES ES17705705T patent/ES2794779T3/es active Active
- 2017-02-10 CR CR20180372A patent/CR20180372A/es unknown
- 2017-02-10 LT LTEP17705705.6T patent/LT3419978T/lt unknown
- 2017-02-10 RS RS20200584A patent/RS60261B1/sr unknown
- 2017-02-10 EP EP17705705.6A patent/EP3419978B1/en active Active
- 2017-02-10 NZ NZ744349A patent/NZ744349A/en unknown
- 2017-02-10 PT PT177057056T patent/PT3419978T/pt unknown
- 2017-02-10 WO PCT/IB2017/050748 patent/WO2017144995A1/en not_active Ceased
- 2017-02-10 HU HUE17705705A patent/HUE049305T2/hu unknown
- 2017-02-10 MD MDE20190031T patent/MD3419978T2/ro unknown
- 2017-02-10 TN TNP/2018/000295A patent/TN2018000295A1/en unknown
- 2017-02-10 GE GEAP201714864A patent/GEP20217242B/en unknown
- 2017-02-10 MA MA052987A patent/MA52987A/fr unknown
- 2017-02-21 CA CA2958490A patent/CA2958490C/en active Active
- 2017-02-21 US US15/437,618 patent/US10144738B2/en active Active
- 2017-02-21 TW TW106105777A patent/TWI665201B/zh active
- 2017-02-22 UY UY0001037133A patent/UY37133A/es unknown
- 2017-02-23 AR ARP170100462A patent/AR107714A1/es active IP Right Grant
2018
- 2018-07-18 SV SV2018005726A patent/SV2018005726A/es unknown
- 2018-07-24 ZA ZA2018/04972A patent/ZA201804972B/en unknown
- 2018-08-01 IL IL260923A patent/IL260923B/en unknown
- 2018-08-03 NI NI201800080A patent/NI201800080A/es unknown
- 2018-08-17 CL CL2018002358A patent/CL2018002358A1/es unknown
- 2018-08-23 PH PH12018501788A patent/PH12018501788A1/en unknown
- 2018-08-24 DO DO2018000187A patent/DOP2018000187A/es unknown
- 2018-09-24 EC ECSENADI201872109A patent/ECSP18072109A/es unknown
- 2018-11-06 US US16/181,596 patent/US10822341B2/en active Active
2020
- 2020-05-15 CY CY20201100470T patent/CY1122949T1/el unknown
- 2020-09-08 US US17/014,533 patent/US11472809B2/en active Active
2022
- 2022-09-07 US US17/939,375 patent/US12129256B2/en active Active

Also Published As

Publication number	Publication date
DOP2018000187A (es)	2019-01-31
JP2019510003A (ja)	2019-04-11
EP3419978B1 (en)	2020-04-15
RU2018130547A3 (da)	2020-03-25
PT3419978T (pt)	2020-06-01
PL3419978T3 (pl)	2020-11-30
EP3712153A1 (en)	2020-09-23
US20230045252A1 (en)	2023-02-09
UY37133A (es)	2017-09-29
IL260923B (en)	2022-01-01
MD3419978T2 (ro)	2020-07-31
TN2018000295A1 (en)	2020-01-16
ZA201804972B (en)	2019-06-26
CR20180372A (es)	2018-09-19
CY1122949T1 (el)	2021-10-29
EA201891463A1 (ru)	2019-03-29
MY189118A (en)	2022-01-26
ME03743B (me)	2021-04-20
NI201800080A (es)	2018-11-22
US10144738B2 (en)	2018-12-04
WO2017144995A1 (en)	2017-08-31
CL2018002358A1 (es)	2018-11-30
HK1258157A1 (zh)	2019-11-08
SI3419978T1 (sl)	2020-08-31
MA43668B1 (fr)	2020-05-29
KR20180103158A (ko)	2018-09-18
BR112018015501A2 (pt)	2018-12-18
LT3419978T (lt)	2020-06-10
CN109071546B (zh)	2021-03-02
SG11201806307YA (en)	2018-09-27
AU2017222417A1 (en)	2018-08-02
CU20180078A7 (es)	2019-02-04
EP3712153B1 (en)	2021-12-01
US11472809B2 (en)	2022-10-18
ECSP18072109A (es)	2018-10-31
GEP20217242B (en)	2021-04-12
US20190071448A1 (en)	2019-03-07
US20170240552A1 (en)	2017-08-24
TW201741313A (zh)	2017-12-01
SV2018005726A (es)	2018-10-24
TWI665201B (zh)	2019-07-11
NZ744349A (en)	2023-06-30
RS60261B1 (sr)	2020-06-30
RU2018130547A (ru)	2020-03-25
CA2958490A1 (en)	2017-08-24
CO2018008799A2 (es)	2018-09-20
CA2958490C (en)	2024-02-27
ES2794779T3 (es)	2020-11-19
EA035036B1 (ru)	2020-04-20
CU24511B1 (es)	2021-05-12
KR102128671B1 (ko)	2020-06-30
US12129256B2 (en)	2024-10-29
US10822341B2 (en)	2020-11-03
MX383747B (es)	2025-03-14
AU2017222417B2 (en)	2020-07-09
MA52987A (fr)	2021-04-28
RU2718902C2 (ru)	2020-04-15
UA119835C2 (uk)	2019-08-12
AR107714A1 (es)	2018-05-23
PH12018501788A1 (en)	2019-06-17
EP3419978A1 (en)	2019-01-02
CN109071546A (zh)	2018-12-21
HUE049305T2 (hu)	2020-09-28
US20200399281A1 (en)	2020-12-24
HRP20200781T1 (hr)	2020-07-24
MX2018010236A (es)	2019-01-14
JP6505956B2 (ja)	2019-04-24

Publication	Publication Date	Title
DK3419978T3 (da)	2020-06-02	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
DK3523301T3 (da)	2020-08-03	Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da)	2022-08-01	Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3322706T3 (da)	2021-02-01	Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
IL266305B (en)	2021-10-31	History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
DK3134413T3 (da)	2019-10-14	Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
IL261231B (en)	2021-10-31	Substituted (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one mcl-1 inhibitors
DK3478682T3 (da)	2021-09-13	[1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
EP3107914B8 (en)	2019-07-17	Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
EP3268000A4 (en)	2018-08-22	Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
DK3227297T3 (da)	2021-04-06	4,6-substitueret-pyrazolo[1,5-a]pyraziner som janus kinase-inhibitorer
DK3478681T3 (da)	2020-03-23	1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
IL247947B (en)	2019-03-31	7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
IL290419B (en)	2022-10-01	Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL247948B (en)	2019-03-31	7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors
IL262673A (en)	2018-12-31	A pyrazolo[5,1-a]pyrimidine compound
DK3679042T3 (da)	2023-05-01	Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
DK3840832T3 (da)	2024-01-15	Imidazo[1,2-b]pyridaziner som trk-inhibitorer
IL258070A (en)	2018-05-31	Cyclic ether history of pyrazolo[5,1-a]pyrimidine-3-carboxamide
DK3194408T3 (da)	2019-07-15	Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor
HUE052997T2 (hu)	2021-06-28	JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok
TH1601001194A (th)	2017-10-19	อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่
TH1601003657A (th)	2018-03-08	อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส